<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444961</url>
  </required_header>
  <id_info>
    <org_study_id>17-1355</org_study_id>
    <nct_id>NCT03444961</nct_id>
  </id_info>
  <brief_title>Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis</brief_title>
  <official_title>Comprehensive Visual and Mobility Training Using Computer-Assisted Rehabilitation Environment (CAREN) After Argus Retinal Prosthesis Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the current project is to fill the unmet clinical needs around the objective&#xD;
      assessment of visual function and develop outcome-oriented visual rehabilitation approach&#xD;
      using the computer assisted rehabilitation environment (CAREN) system for Argus recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of CAREN Virtual Reality System on Obstacle Course Navigation</measure>
    <time_frame>6 wks</time_frame>
    <description>Obstacle course navigation - time (seconds) to complete an obstacle course (walking forward while navigating over a ramp and curb)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Complete the Timed Up and Go Test Before and After CAREN Virtual Reality System Training</measure>
    <time_frame>6 wks</time_frame>
    <description>Timed Up and Go testing - functional mobility test that requires the individual to stand from a chair, ambulate three meters to a target, turn around, return to the chair, and sit down. Participants were asked to complete two trials was recorded, with a maximum time of 60 seconds per trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of CAREN Virtual Reality System on Square Localization Visual Function Test</measure>
    <time_frame>6 wks</time_frame>
    <description>The square localization test presents a 2.75&quot; square (250 pixels) at a random location on a black background and the patient is instructed to try to touch the square. The test measures the patient's ability to locate an object and results are calculated as a mean error (how far away in pixels from the square the patient touches the screen). A lower mean error (the distance from the square) indicates better patient performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of CAREN Virtual Reality System on Direction of Motion Visual Function Test.</measure>
    <time_frame>6 wks</time_frame>
    <description>The direction of motion test assesses the patient's ability to determine the direction an object is moving. The patient is presented with a white line (1.4'' wide) that moves across the screen in a random series of directions and angles. Patients are instructed to trace their finger on the monitor in the direction they perceived the line moved. Results are calculated as a mean error (how far off, in degrees, was the patient from the direction of the moving line). The higher the mean error/score, the worse the outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of CAREN Virtual Reality System on Grating Visual Acuity Visual Function Test</measure>
    <time_frame>6 wks</time_frame>
    <description>The grating visual acuity test measures the patient's visual acuity using the principles of acuity charts modified for ultra-low vision subjects. The patients are presented with black and white bars in one of four orientations (horizontal, vertical, diagonal to the left or diagonal to the right). The bars are present on the screen for 5 seconds during which the patient may scan the screen and then provide a verbal response as to which orientation they perceived the bars. The widths of the bars are varied to evaluate different levels of visual acuity. A lower score is associated with better outcomes with 2.9 being the worst possible score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of CAREN Virtual Reality System on Gait Assessment</measure>
    <time_frame>6 wks</time_frame>
    <description>Subject's gait assessed by meters traveled while localizing objects on the CAREN system. The higher scores are associated with better outcomes (further distance walked).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Effects of CAREN Virtual Reality System on Activities-specific Balance Confidence (ABC) Scale Questionnaire</measure>
    <time_frame>6 wks</time_frame>
    <description>The Activities-specific Balance Confidence Scale (ABC Scale) is a structured questionnaire that measures an individual's confidence in performing activities without losing balance. It is a 0% to 100% continuous response scale with 0 representing &quot;no confidence&quot; and 100 representing &quot;complete confidence.&quot;</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>CAREN system training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAREN training</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CAREN system training</intervention_name>
    <description>CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
    <arm_group_label>CAREN system training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient of the Argus II Retinal Prosthesis System&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Ability to follow two-step commands&#xD;
&#xD;
          -  Ability to ambulate 300+ feet with or without visual assistance&#xD;
&#xD;
          -  Able to tolerate Argus device turned on for &gt;20 continuous minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Musculoskeletal contraindication to exercise or walking&#xD;
&#xD;
          -  Cardiopulmonary contraindication exercise (i.e. uncontrolled heart failure, cardiac&#xD;
             arrhythmia, or pulmonary disease).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Rachitskaya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <results_first_submitted>July 25, 2019</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Aleksandra Rachitskaya, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Argus II Retinal Prosthesis System</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03444961/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CAREN System Training</title>
          <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CAREN System Training</title>
          <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of CAREN Virtual Reality System on Obstacle Course Navigation</title>
        <description>Obstacle course navigation - time (seconds) to complete an obstacle course (walking forward while navigating over a ramp and curb)</description>
        <time_frame>6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
          <group group_id="O2">
            <title>Post-CAREN Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CAREN Virtual Reality System on Obstacle Course Navigation</title>
          <description>Obstacle course navigation - time (seconds) to complete an obstacle course (walking forward while navigating over a ramp and curb)</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.25" lower_limit="28" upper_limit="117"/>
                    <measurement group_id="O2" value="33.75" lower_limit="28" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Complete the Timed Up and Go Test Before and After CAREN Virtual Reality System Training</title>
        <description>Timed Up and Go testing - functional mobility test that requires the individual to stand from a chair, ambulate three meters to a target, turn around, return to the chair, and sit down. Participants were asked to complete two trials was recorded, with a maximum time of 60 seconds per trial.</description>
        <time_frame>6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre - CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
          <group group_id="O2">
            <title>Post-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete the Timed Up and Go Test Before and After CAREN Virtual Reality System Training</title>
          <description>Timed Up and Go testing - functional mobility test that requires the individual to stand from a chair, ambulate three meters to a target, turn around, return to the chair, and sit down. Participants were asked to complete two trials was recorded, with a maximum time of 60 seconds per trial.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" spread="6.6"/>
                    <measurement group_id="O2" value="39.29" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of CAREN Virtual Reality System on Square Localization Visual Function Test</title>
        <description>The square localization test presents a 2.75&quot; square (250 pixels) at a random location on a black background and the patient is instructed to try to touch the square. The test measures the patient's ability to locate an object and results are calculated as a mean error (how far away in pixels from the square the patient touches the screen). A lower mean error (the distance from the square) indicates better patient performance.</description>
        <time_frame>6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
          <group group_id="O2">
            <title>Post-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CAREN Virtual Reality System on Square Localization Visual Function Test</title>
          <description>The square localization test presents a 2.75&quot; square (250 pixels) at a random location on a black background and the patient is instructed to try to touch the square. The test measures the patient's ability to locate an object and results are calculated as a mean error (how far away in pixels from the square the patient touches the screen). A lower mean error (the distance from the square) indicates better patient performance.</description>
          <units>pixels</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.62" lower_limit="104.12" upper_limit="463.47"/>
                    <measurement group_id="O2" value="245.43" lower_limit="104.12" upper_limit="463.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of CAREN Virtual Reality System on Direction of Motion Visual Function Test.</title>
        <description>The direction of motion test assesses the patient's ability to determine the direction an object is moving. The patient is presented with a white line (1.4'' wide) that moves across the screen in a random series of directions and angles. Patients are instructed to trace their finger on the monitor in the direction they perceived the line moved. Results are calculated as a mean error (how far off, in degrees, was the patient from the direction of the moving line). The higher the mean error/score, the worse the outcome.</description>
        <time_frame>6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
          <group group_id="O2">
            <title>Post-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CAREN Virtual Reality System on Direction of Motion Visual Function Test.</title>
          <description>The direction of motion test assesses the patient's ability to determine the direction an object is moving. The patient is presented with a white line (1.4'' wide) that moves across the screen in a random series of directions and angles. Patients are instructed to trace their finger on the monitor in the direction they perceived the line moved. Results are calculated as a mean error (how far off, in degrees, was the patient from the direction of the moving line). The higher the mean error/score, the worse the outcome.</description>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.68" lower_limit="14.51" upper_limit="95.16"/>
                    <measurement group_id="O2" value="58.12" lower_limit="14.51" upper_limit="95.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of CAREN Virtual Reality System on Grating Visual Acuity Visual Function Test</title>
        <description>The grating visual acuity test measures the patient's visual acuity using the principles of acuity charts modified for ultra-low vision subjects. The patients are presented with black and white bars in one of four orientations (horizontal, vertical, diagonal to the left or diagonal to the right). The bars are present on the screen for 5 seconds during which the patient may scan the screen and then provide a verbal response as to which orientation they perceived the bars. The widths of the bars are varied to evaluate different levels of visual acuity. A lower score is associated with better outcomes with 2.9 being the worst possible score.</description>
        <time_frame>6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CAREN Virtual Reality System on Grating Visual Acuity Visual Function Test</title>
          <description>The grating visual acuity test measures the patient's visual acuity using the principles of acuity charts modified for ultra-low vision subjects. The patients are presented with black and white bars in one of four orientations (horizontal, vertical, diagonal to the left or diagonal to the right). The bars are present on the screen for 5 seconds during which the patient may scan the screen and then provide a verbal response as to which orientation they perceived the bars. The widths of the bars are varied to evaluate different levels of visual acuity. A lower score is associated with better outcomes with 2.9 being the worst possible score.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" lower_limit="1.7" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of CAREN Virtual Reality System on Gait Assessment</title>
        <description>Subject's gait assessed by meters traveled while localizing objects on the CAREN system. The higher scores are associated with better outcomes (further distance walked).</description>
        <time_frame>6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
          <group group_id="O2">
            <title>Post-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CAREN Virtual Reality System on Gait Assessment</title>
          <description>Subject's gait assessed by meters traveled while localizing objects on the CAREN system. The higher scores are associated with better outcomes (further distance walked).</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.05" lower_limit="72.84" upper_limit="159.70"/>
                    <measurement group_id="O2" value="130.7" lower_limit="72.84" upper_limit="159.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effects of CAREN Virtual Reality System on Activities-specific Balance Confidence (ABC) Scale Questionnaire</title>
        <description>The Activities-specific Balance Confidence Scale (ABC Scale) is a structured questionnaire that measures an individual's confidence in performing activities without losing balance. It is a 0% to 100% continuous response scale with 0 representing &quot;no confidence&quot; and 100 representing &quot;complete confidence.&quot;</description>
        <time_frame>6 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
          <group group_id="O2">
            <title>Post-CAREN System Training</title>
            <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CAREN Virtual Reality System on Activities-specific Balance Confidence (ABC) Scale Questionnaire</title>
          <description>The Activities-specific Balance Confidence Scale (ABC Scale) is a structured questionnaire that measures an individual's confidence in performing activities without losing balance. It is a 0% to 100% continuous response scale with 0 representing &quot;no confidence&quot; and 100 representing &quot;complete confidence.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.125" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="34.375" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE's were collected over the course of 6 months while patients were enrolled/actively participating in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CAREN System Training</title>
          <description>CAREN training&#xD;
CAREN system training: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Aleksandra Rachitskaya</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-9519</phone>
      <email>rachita@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

